ABSTRACT
This chapter describes trade name, classification, approved indications for psychological disorders, available dosage forms, storage, and compatibility, usual dosage and administration, relative contraindications, and clinically significant drug interactions of Oxazepam. Oxazepam also is not recommended for the management of anxiety associated with depression because it has the potential to exacerbate the depression while alleviating the anxiety. Oxazepam pharmacotherapy during pregnancy has been associated with cleft lip and palate among neonates. In addition, an increased risk for congenital malformations has been associated with other benzodiazepine pharmacotherapy, including chlordiazepoxide and diazepam pharmacotherapy. Oxazepam is excreted in low concentrations in breast milk. Although concentrations are low, the half-life of oxazepam will be significantly prolonged among breast-fed neonates during the first week following birth because of their immature kidney and liver function. Elderly, frail, or debilitated patients may be more sensitive to the pharmacologic actions of oxazepam than are younger or healthier adult patients.
